- Home
- IKNA vs TNXP Comparison
IKNA vs TNXP Comparison
Compare IKNA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- TNXP
- Stock Information
- Founded
- IKNA 2016
- TNXP 2007
- Country
- IKNA United States
- TNXP United States
- Employees
- IKNA N/A
- TNXP N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- TNXP Health Care
- Exchange
- IKNA Nasdaq
- TNXP Nasdaq
- Market Cap
- IKNA 64.7M
- TNXP 71.6M
- IPO Year
- IKNA 2021
- TNXP N/A
- Fundamental
- Price
- IKNA $1.32
- TNXP $20.17
- Analyst Decision
- IKNA Buy
- TNXP Strong Buy
- Analyst Count
- IKNA 2
- TNXP 2
- Target Price
- IKNA $3.00
- TNXP $585.00
- AVG Volume (30 Days)
- IKNA 84.4K
- TNXP 2.5M
- Earning Date
- IKNA 03-06-2025
- TNXP 03-18-2025
- Dividend Yield
- IKNA N/A
- TNXP N/A
- EPS Growth
- IKNA N/A
- TNXP N/A
- EPS
- IKNA N/A
- TNXP N/A
- Revenue
- IKNA N/A
- TNXP $10,094,000.00
- Revenue This Year
- IKNA N/A
- TNXP $84.08
- Revenue Next Year
- IKNA N/A
- TNXP $126.94
- P/E Ratio
- IKNA N/A
- TNXP N/A
- Revenue Growth
- IKNA N/A
- TNXP 29.94
- 52 Week Low
- IKNA $1.22
- TNXP $6.76
- 52 Week High
- IKNA $1.94
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- IKNA 43.56
- TNXP 51.57
- Support Level
- IKNA $1.27
- TNXP $12.80
- Resistance Level
- IKNA $1.43
- TNXP $31.87
- Average True Range (ATR)
- IKNA 0.07
- TNXP 4.00
- MACD
- IKNA 0.00
- TNXP 1.21
- Stochastic Oscillator
- IKNA 37.21
- TNXP 30.69
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.